Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Kalaris Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 51
- +19 vs. Q3 2025
- Shares held
- 18.0M
- +4.77M (+36.1%) vs. Q3 2025
- Total value
- $151.9M
- +$75.5M (+98.7%) vs. Q3 2025
- New holders
- 24
- 10 more added
- Sold out
- 5
- 7 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KLRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $73.4M |
| Q1 2026 | 58 | $107.2M |
| Q4 2025 | 51 | $151.9M |
| Q3 2025 | 32 | $76.4M |
| Q2 2025 | 30 | $35.7M |
| Q1 2025 | 32 | $111.4M |
| Q4 2024 | 53 | $20.7M |
| Q3 2024 | 60 | $36.3M |
| Q2 2024 | 72 | $33.9M |
| Q1 2024 | 77 | $36.4M |
| Q4 2023 | 82 | $28.5M |
| Q3 2023 | 90 | $115.5M |
| Q2 2023 | 94 | $183.6M |
| Q1 2023 | 89 | $156.0M |
| Q4 2022 | 86 | $193.1M |
| Q3 2022 | 87 | $293.7M |
| Q2 2022 | 84 | $109.6M |
| Q1 2022 | 84 | $184.1M |
| Q4 2021 | 84 | $329.4M |
| Q3 2021 | 80 | $640.3M |
| Q2 2021 | 84 | $521.8M |
| Q1 2021 | 75 | $624.4M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Kalaris Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citigroup Inc | 1 | $8 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 5 | $42 | 0.00% | −3−37.5% | Reduced |
| Parallel Advisors, LLC | 49 | $414 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 50 | $422 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 52 | $439 | 0.00% | −89−63.1% | Reduced |
| Fortitude Family Office, LLC | 114 | $962 | 0.00% | +114 | New |
| Royal Bank of Canada | 113 | $1.00K | 0.00% | +28+32.9% | Added |
| UBS Group AG | 2,691 | $22.7K | 0.00% | −2,561−48.8% | Reduced |
| Nano Cap New Millennium Growth Fund L P | 4,000 | $33.8K | 0.03% | +4,000 | New |
| Barclays PLC | 6,065 | $51.2K | 0.00% | +6,065 | New |
| Bank of America Corp | 6,704 | $56.6K | 0.00% | +6,487+2,989.4% | Added |
| FMR LLC | 7,806 | $65.9K | 0.00% | 00.0% | Unchanged |
| Johnson Financial Group, Inc. | 10,000 | $84.4K | 0.00% | 00.0% | Unchanged |
| Connor, Clark & Lunn Investment Management Ltd. | 10,159 | $85.7K | 0.00% | +10,159 | New |
| Keel Point, LLC | 10,225 | $86.3K | 0.01% | +10,225 | New |
| XTX Topco Ltd | 10,897 | $92.0K | 0.00% | +10,897 | New |
| Walleye Capital LLC | 11,225 | $94.7K | 0.00% | +11,225 | New |
| Susquehanna International Group, LLP | 12,856 | $108.5K | 0.00% | +12,856 | New |
| Northern Trust Corp | 13,654 | $115.2K | 0.00% | +13,654 | New |
| RBF Capital, LLC | 17,391 | $146.8K | 0.01% | 00.0% | Unchanged |
| Simplify Asset Management Inc. | 20,074 | $169.4K | 0.00% | +20,074 | New |
| Bridgeway Capital Management, LLC | 22,500 | $189.9K | 0.00% | 00.0% | Unchanged |
| Squarepoint Ops LLC | 25,367 | $214.1K | 0.00% | −14,806−36.9% | Reduced |
| State Street Corp | 25,410 | $214.5K | 0.00% | +2,800+12.4% | Added |
| Two Sigma Investments, LP | 27,759 | $234.3K | 0.00% | +27,759 | New |
| Morgan Stanley | 27,948 | $235.9K | 0.00% | +3,030+12.2% | Added |
| Omers Administration Corp | 30,000 | $253.2K | 0.00% | +30,000 | New |
| Jane Street Group, LLC | 33,114 | $279.5K | 0.00% | +33,114 | New |
| Goldman Sachs Group Inc | 34,303 | $289.5K | 0.00% | +11,838+52.7% | Added |
| BlackRock, Inc. | 38,454 | $324.6K | 0.00% | −1,925−4.8% | Reduced |
| Belpointe Asset Management LLC | 40,000 | $337.6K | 0.01% | 00.0% | Unchanged |
| Fortis Capital Advisors, LLC | 40,000 | $337.6K | 0.05% | 00.0% | Unchanged |
| Propel Bio Management, LLC | 42,053 | $354.9K | 0.30% | +42,053 | New |
| Marshall Wace, LLP | 72,876 | $615.1K | 0.00% | +58,761+416.3% | Added |
| 683 Capital Management, LLC | 80,590 | $680.2K | 0.06% | +80,590 | New |
| Geode Capital Management, LLC | 82,647 | $697.6K | 0.00% | +18,096+28.0% | Added |
| Redmile Group, LLC | 82,955 | $700.1K | 0.05% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 87,751 | $740.6K | 0.00% | −25,000−22.2% | Reduced |
| Raymond James Financial Inc | 88,436 | $746.4K | 0.00% | +88,436 | New |
| Boothbay Fund Management, LLC | 92,261 | $778.7K | 0.02% | +92,261 | New |
| Whi Trust Co LLC | 97,493 | $822.8K | 0.63% | +97,493 | New |
| Woodline Partners LP | 100,000 | $844.0K | 0.00% | −141,102−58.5% | Reduced |
| ADAR1 Capital Management, LLC | 100,000 | $844.0K | 0.06% | +100,000 | New |
| Kalehua Capital Management LLC | 139,901 | $1.18M | 1.17% | +139,901 | New |
| Vanguard Group Inc | 292,790 | $2.47M | 0.00% | +89,739+44.2% | Added |
| Ikarian Capital, LLC | 360,000 | $3.04M | 0.39% | +360,000 | New |
| Alyeska Investment Group, L.P. | 403,551 | $3.40M | 0.01% | +403,551 | New |
| Siren, L.L.C. | 435,798 | $3.68M | 0.11% | +117,534+36.9% | Added |
| Paradigm Biocapital Advisors LP | 700,000 | $5.91M | 0.16% | +700,000 | New |
| RTW Investments, LP | 1,300,000 | $11.0M | 0.11% | +1,300,000 | New |
| Samsara BioCapital, LLC | 12,948,081 | $109.3M | 11.27% | +1,500,000+13.1% | Added |
| Tang Capital Management LLC | 0 | $0 | 0.00% | −418,241−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −24,923−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −578−100.0% | Sold out |
| Strengthening Families & Communities, LLC | 0 | $0 | 0.00% | −268−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −33−100.0% | Sold out |